Quiz #3 Material Flashcards

1
Q

Hemostasis: four major events occur following a wound

A
  • VPCF
  • Vascular Constriction:
    • Limits the flow of blood to the injury
  • Platelet aggregation:
    • Blood platelets clump when binding to collagen that becomes exposed following rupture. Blood platelets become activated and aggregate at the site of injury
  • Clot formation:
    • To inure stability of the initially loose platelet plug, a fibrin mesh (aka clot) forms and entraps the plug
  • Fibrinolysis:
    • The clot must be dissolved in order for normal blood flow to resume following tissue repair. The dissolution of the clot occurs through the action of plasmin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Platelets

A
  • Platelets are NOT cells but really just a type of vesicle that pinches off of the megakaryocyte.
  • No nucleus
  • Hemopoetic stem cell→Promegakaryocyte→Megakaryocyte→Platelet
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Major Drugs Acting on Platelets:

  • ADP antagonists
  • PDE Inhibitor
  • Platelet surface bind
  • COX inhibitor
  • (Multiple Mechanisms)
A
  • ADP antagonists
    • Clopidogrel (Plavix)
    • Ticlopidine (Ticlid)
    • Prasugrel (Ticagrelor)
  • PDE Inhibitor
    • Dipyridamole (Aggrenox)
  • Platelet surface bind
    • Abciximab (ReoPro)
    • Tirofiban (Aggrastat)
    • Eptifibatide (Integrelin)
  • COX inhibitor
    • Aspirin
  • (Multiple Mechanisms)
    • Thrombin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Three Steps of Clot Formation

A
  • Activation
    • Activation/Adhesion of platelets
  • Release
    • Release of factors to drive the activation and adhesion of platelets (ADP, thromboxane A2)
  • Recruitment
    • Recruitment of more platelets, aggregation and formation of a clot
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Important Concept of Platelet Aggregation Mechanism

A
  • Works on a feed-forward mechanism
  • Is turned off by excretions from the endothelium
    • EDRF, PGI2, tPA, and heparin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Thrombin

A
  • Factor IIa
  • Cleaves N-terminus of PAR-1
    • Leaves behind a ‘tethered ligand’ that can provide continuous activity of the receptor until receptor recycling
    • Irreversible (actually slowly reversible)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Molecular Basis of Platelet Aggregation and Activation

A
  • Collagen/damaged endothelium bind Von Willebrand Factor which in turn has high affinity for GP1b/Gp IIb
  • Gp Ia: platelet receptor for collagen
  • Gp Ib: platelet receptor for VWF
  • Gp IIb-IIIa: integrin that binds fibrin
  • Antagonists to GpIIb/IIIa prevent binding to fibrin
    • Abciximab (Reopro): coronoary artery procedures to prevent platelet sticking
    • Tirofiban (RGD)
    • Eptifibatide (Integrilin, C-term of fibrinogen)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Synthesis and Effects of Arachadonic Acid Metabolites

A
  • COX Enzymes metabolize arachadonic acid, leading to the production of thromboxanes and prostacyclin
    • Thromboxanes: made in platelets and lead to increased platelet aggregration
    • Prostacylin: made in endothelial tissue and lead to decreased platelet aggregation
      • opposing factors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Action of Aspirin

A
  • Irreversibly inhibits COX to inhibit both:
    • Inhibits thrombaxane synthesis: decrease in platelet aggregation
      • Can’t be produced by COX enzmes until platelets are fully recycled
    • Inhibits prostacyclin synthesis
      • Can be recovered because endothelial cells have nuclei
  • Aspirin + PGHS2→Salicylic acid + acetylated PGHS2
  • Use low dose:
    • Platelet COX1 has highest affinity for aspirin
    • Aspirin doesn’t inhibit endothelium COX1
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Ibuprofen and other NSAIDS

A
  • Other NSAIDs don’t work for clotting because they are reversible
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Ticlid and Plavix

A
  • Thienopyridines
  • ADP receptor antagonists
  • Prevent recuring DVT, strokes and intermittent claudication
  • Plavix (clopidogrel)
    • Requires activation by CYP2C19
    • Low dose ASA + Plavix not more effective than ASA alone
    • Thrombocytic thrombocytopenia
  • Ticlid (ticlopidine)
    • Safety? bleeds and hemorraging
  • THM: Covalent/Irreversible
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

newer ADP receptor antagonists

A
  • Prasugrel (Effient)
    • Requires enzymatic activation
    • Noncompetitive antagonist at the P2Y12 purinergic receptor
  • Ticagrelor (Brilinta)
    • Reversible allosteric agonist
  • Better safety and efficacy when used in combo with ASA?
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Dipyridamole

A
  • Dipyridamole (Persantin)
  • Cilostazol, PDE3 inihibitor, approved for intermittent claudication
  • Aggrenox
    • Dipyridamole with tartaric acid to solubilize
    • Sustained release pellets with ASA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Factors on platelet surface involed in clot formation

A
  • GpIa: receptor for collagen
  • GpIb: receptor of VWF
  • GpIIb-GpIIIa: integrin that binds fibrin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

ADP Receptor Antagonists: MOA and Example

A
  • Block the ADP receptor from being activated by ADP→block platelet adhesion
    • Plavix (clopidegrel) falls into this category
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Clotting Cascade: Key Players

A
  • Xa: converts prothrombin→thrombin
  • IIa: thrombin; converts fibrinogen→fibrin
  • XIIIa: transglutaminase enzyme that converts soluble fibrin to insoluable fibrin, the final step of the clotting cascade
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Direct vs. Indirect clotting cascade effectors: General MOA and examples

A
  • Indirect Effectors:
    • Doesn’t directly effect coagulation cascade factors
    • Warfarin
  • Direct Effectors:
    • Directly effects coagulation cascade factors
    • Antibodies
    • Heparin
18
Q

Warfarin Mechanism

A
  • Indirect effector
  • Vitamin K analog→binds and inhibits the recycling of factors that drive the ‘active’ prothrombin
  • Very NTI
  • Easily reversible with vitamin K
19
Q

Antibody Anticoagulants Mechanism

A
  • Direct effectors
  • Inhibit the enzymes in the cascade by preventing their action
  • Ex: dabigatran blocks IIa in converting fibrin→fibrinogen
  • Do not require a cofactor
20
Q

Heparin Mechansim

A
  • Direct Effector
  • Endogenous
  • Form a complex with antithrombin III
  • Act quickly
  • Inhibts the actions of factor Xa and IIa (thrombin)
  • LMW heparins can be more specific
  • Reversal with protamine sulfate
21
Q

What is coagulation controlled physiologically by?

A
  • Plasma Protease Inhibitors
    • inhibit many of the coagulation factors
  • Protein C
    • active protease which drives fibrinolytic action
    • This is often a cause of bleeding following warfarin withdrawal
22
Q

How to dissolve a clot

A
  • Thrombolytics/fibrinolytics
  • Tissue plasminogen activator (tPA)
  • Streptokinase
  • Urokinase
23
Q

tPA Mechansim

A
  • Is made by healthy endothelial tissues and converts plasminogen to plasmin (an active protease which drives the breakdown of insoluable fibrin clots)
    • Acts by having an increased affinity for fibrin-bound plasminogen (to activate it to fibrin)
  • protease
24
Q

Streptokinase MOA

A
  • Binds to plasminogen and the complex activates a second plasminogen molecule to active plasmin
  • Direct binding activator
25
Q

Urokinase MOA

A
  • Proteolytically activates plasminogen directly
  • A protease
26
Q

Apixaban and Rivaroxaban

A

Factor Xa

27
Q

Lepirudin

A
  • Recombinant form of hirudin
  • From leach
  • Direct thrombin inhibitor
28
Q

Heparin and Fondaparinux

A
  • Heparin pentasaccharide binds to anti-thrombin III
    • Accelerates interaction with Xa
    • When thrombin binds complex, needs tail to loop around to inhibit
      • Need to be at least 18 saccharide units (5400 Da)
  • Fondapurinux (1500 Da): LMWH heparin less likely to bind to ATIII:IIa and inhibit it
  • If only have the pentasaccharide, only acceleratie ATIII:Xa inhibition
29
Q

How are coagulation reaction limited?

A
  • Endothelial health
    • PGI2, EDRF
  • Plasma protease inhibitors:
    • Excess (anti-thrombin III)
    • Remember endothelium makes heparin
  • Thrombomodulin/Protein C:
    • Another endothelial/thrombin dependent pathway
30
Q

Thrombin/Thrombomodulin Model of Protein C Action

A
  • Thrombin bound to thrombomodulin
    • endothelial surface
    • cleaves protein C to activated protein C
    • Cleaves factors Va and VIIIa to give inactive products→Anticoagulant activity
  • process is accelerated in the presence of protein S and platelets
  • Both protein C and protein S are GLA-containing proteins, are vitamin K-dependent, and are affected by warfarin.
    • Inactivates tPA inhibitor→increases tPA activity→fibrinolytic action
  • Protein C has most rapid turn over of any Ca2+ dependent proteases
31
Q

Clinical Significance of Thrombolytic Therapy

A
  • 80% of MI never get thrombolytic treatment
  • Delivery is a big problem
  • Time to treatment is cruical for stroke
    • is it a hemorrhagic stroke?
    • needs to be within 3+ hours
32
Q

Lipoproteins: Why do we need to be concerned?

A
  • High LDL cholestrol is poitvely associated with increased risk of coronary artery disease and death
  • Clog, break off, exposed phospholipid surface that starts coagulation rxn
33
Q

The order of cholesterol transport

A
  • Gut: chylomicron→VLDL→LDL→IDL→HDL: Liver
  • Needed to transport and store chlesterol around the body
  • Very hydrophobic and wouldn’t be able to move freely in body’s water-based environment
34
Q

Chylomicrons

A
  • Deliver triglycerides derived from dietary fat to non-hepatic tissues
    • Apolipoproteins: B48, CII and CIII
      • Act as cofactors for lipoprotein lipase and allow interaction with downstream molecules for dilevery to fat cells
35
Q

VLDL

A
  • Deliver triglycerides derived from liver synthesis to non-hepatic tissues
  • Apolipoproteins: C, E, B100
    • B100 is same gene as B48, but longer→allows for binding to LDL receptor
36
Q

LDL

A
  • Derived from VLDL and deliver cholesterol derived from liver synthesis to various tissues
  • Apoliprotein B:
    • Has same B100 protein to bind LDL receptor
37
Q

HDL

A
  • Collect (scavenge) cholesterol from non-hepatic tissues and deliver to the liver
  • ApoA-I and ApoA-II
    • Remove excess cholesterol from foam cells and transport to where they may be less toxic
    • Role is to remove ‘free cholesterol’ and convert to cholesterol esters and deliver to liver or steroidogenic tissue (uses SR-B1)
    • Cholesterol can be transferred to other lipoproteins by CETP
  • ApoC: cofactor with lipase to break down triglycerides
38
Q

What must be true about B100 for it to bind LDL receptor

A
  • Must be oxidized
39
Q

Lp(A)

A
  • Very artherogenic form of lipoprotein
  • More/longer coiled “pringles” make them more artherogenic
  • Form disulfide bond with B100
  • Plaque promoting
  • Things that lower LDL also lower Lp(A) because half of Lp(A) is LDL
40
Q

Framingham Study

A
  • High ration of HDL to total cholesterol is often protective
    • We now know not ALL forms of HDL are ‘good’
    • We particularly want HDL3